...TP53, BRCA1, BRCA2, FANCA, SLX4, RAD50, MSH6, POLD1 and NF1. Four patients (36.4%) carried PVs/LPVs in canonical FA path...
...TP53 wild-type colorectal cancers, and the latter was upregulated in both wild-type and mutant TP53 cancers. Upregulatio...
...TP53mut tumors were more frequently associated with adverse clinicopathological features and showed lower and heterogene...
...TP53 UV-radiation signature in both. However, while AFX and PDS share common DNA mutation profiles in our cohort, RNA se...
...TP53, SMAD4), although trends toward co-occurrence with BRAF mutation and mutual exclusivity with HER2 amplification wer...
...TP53 (≈35%), STAG2 (≈25%), and PIK3CA (≈20%), consistent with established molecular pathways in UBC. Less frequent but p...
...TP53 (9.3%) and SETD2 (8.3%) genes. Several pathways were found as potential treatment targets including the chromatin r...
...TP53, HER2, EGFR, and PD-L1 exhibit cross-species conservation, supporting the relevance of companion animals in biomark...
...TP53, MAPK3, HIF1A and BCL2. Molecular docking and molecular dynamics simulations indicate that Paeoniflorin exhibits st...
...TP53-mutated AML. In the NGS era, the diagnostic-to-treatment interval should be viewed as an active, biologically infor...
联系地址
山东省济南市章丘区文博路2号
齐鲁师范学院 genelibs生信实验室
山东省济南市高新区舜华路750号
大学科技园北区F座4单元2楼
电话： 0531-88819269
版权所有 © 2026.Genelibs 济南弘晖生物技术有限公司 鲁ICP备20007159号-2
